Total Payments
$466.34
2024 Payments
$63.04
Companies
9
Transactions
33
Medicare Patients
1,211
Medicare Billing
$270,036
Payment Breakdown by Category
Food & Beverage$441.05 (94.6%)
Education$25.29 (5.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $441.05 | 31 | 94.6% |
| Education | $25.29 | 2 | 5.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $134.51 | 8 | $0 (2024) |
| Sunovion Pharmaceuticals Inc. | $111.95 | 13 | $0 (2018) |
| Exeltis, USA Inc. | $81.58 | 3 | $0 (2022) |
| Mallinckrodt Hospital Products Inc. | $34.59 | 2 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $31.91 | 2 | $0 (2022) |
| Merck Sharp & Dohme Corporation | $25.29 | 2 | $0 (2020) |
| Actelion Pharmaceuticals US, Inc. | $20.77 | 1 | $0 (2024) |
| Covidien LP | $14.52 | 1 | $0 (2019) |
| AstraZeneca Pharmaceuticals LP | $11.22 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $63.04 | 3 | GlaxoSmithKline, LLC. ($22.87) |
| 2022 | $136.40 | 6 | Exeltis, USA Inc. ($81.58) |
| 2021 | $49.99 | 3 | GlaxoSmithKline, LLC. ($20.26) |
| 2020 | $52.33 | 4 | GlaxoSmithKline, LLC. ($39.74) |
| 2019 | $38.44 | 3 | Covidien LP ($14.52) |
| 2018 | $126.14 | 14 | Sunovion Pharmaceuticals Inc. ($111.95) |
All Payment Transactions
33 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/20/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug), UPTRAVI | Food and Beverage | In-kind items and services | $20.77 | General |
| Category: Cardiology | ||||||
| 08/13/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $19.40 | General |
| Category: IMMUNOLOGY | ||||||
| 05/25/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $22.87 | General |
| Category: IMMUNOLOGY | ||||||
| 11/15/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $17.37 | General |
| Category: RESPIRATORY | ||||||
| 10/28/2022 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $16.27 | General |
| Category: RESPIRATORY | ||||||
| 05/10/2022 | Exeltis, USA Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $32.39 | General |
| Category: Treatment of certain chronic autoimmune disorders, including acute exacerbations of MS and RA | ||||||
| 05/02/2022 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $21.18 | General |
| Category: RESPIRATORY | ||||||
| 04/11/2022 | Exeltis, USA Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $18.32 | General |
| Category: Treatment of certain chronic autoimmune disorders, including acute exacerbations of MS and RA | ||||||
| 03/02/2022 | Exeltis, USA Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $30.87 | General |
| Category: Treatment of certain chronic autoimmune disorders, including acute exacerbations of MS and RA | ||||||
| 11/29/2021 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $15.19 | General |
| Category: IMMUNOLOGY | ||||||
| 05/20/2021 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $20.26 | General |
| Category: RESPIRATORY | ||||||
| 01/25/2021 | Boehringer Ingelheim Pharmaceuticals, Inc. | STIOLTO RESPIMAT (Drug) | Food and Beverage | In-kind items and services | $14.54 | General |
| Category: RESPIRATORY | ||||||
| 08/10/2020 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug) | Education | In-kind items and services | $12.59 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 08/10/2020 | GlaxoSmithKline, LLC. | ANORO ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $11.06 | General |
| Category: RESPIRATORY | ||||||
| 04/28/2020 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $13.45 | General |
| Category: RESPIRATORY | ||||||
| 04/09/2020 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $15.23 | General |
| Category: RESPIRATORY | ||||||
| 12/12/2019 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug) | Education | In-kind items and services | $12.70 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 09/08/2019 | Covidien LP | Valleylab (Device) | Food and Beverage | In-kind items and services | $14.52 | General |
| Category: Electrosurgical Products | ||||||
| 04/18/2019 | AstraZeneca Pharmaceuticals LP | SYMBICORT (Drug) | Food and Beverage | In-kind items and services | $11.22 | General |
| Category: Respiratory | ||||||
| 12/20/2018 | Sunovion Pharmaceuticals Inc. | LONHALA MAGNAIR (Drug) | Food and Beverage | In-kind items and services | $9.31 | General |
| Category: Respiratory | ||||||
| 12/03/2018 | Sunovion Pharmaceuticals Inc. | LONHALA MAGNAIR (Drug) | Food and Beverage | In-kind items and services | $11.95 | General |
| Category: Respiratory | ||||||
| 11/06/2018 | Sunovion Pharmaceuticals Inc. | LONHALA MAGNAIR (Drug) | Food and Beverage | In-kind items and services | $10.41 | General |
| Category: Respiratory | ||||||
| 10/12/2018 | Sunovion Pharmaceuticals Inc. | LONHALA MAGNAIR (Drug) | Food and Beverage | In-kind items and services | $11.94 | General |
| Category: Respiratory | ||||||
| 10/08/2018 | Sunovion Pharmaceuticals Inc. | LONHALA MAGNAIR (Drug) | Food and Beverage | In-kind items and services | $10.25 | General |
| Category: Respiratory | ||||||
| 10/05/2018 | Sunovion Pharmaceuticals Inc. | LONHALA MAGNAIR (Drug) | Food and Beverage | In-kind items and services | $5.63 | General |
| Category: Respiratory | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 168 | 385 | $160,058 | $41,862 |
| 2022 | 8 | 248 | 692 | $329,390 | $75,761 |
| 2021 | 10 | 279 | 574 | $194,286 | $50,239 |
| 2020 | 12 | 516 | 1,241 | $419,337 | $102,174 |
Total Patients
1,211
Total Services
2,892
Medicare Billing
$270,036
Procedure Codes
35
All Medicare Procedures & Services
35 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 29 | 108 | $67,392 | $17,742 | 26.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 42 | 95 | $50,350 | $12,618 | 25.1% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 26 | 75 | $22,425 | $6,832 | 30.5% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2023 | 44 | 80 | $9,280 | $2,411 | 26.0% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 27 | 27 | $10,611 | $2,259 | 21.3% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 36 | 226 | $185,998 | $38,888 | 20.9% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 41 | 152 | $45,448 | $12,245 | 26.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 34 | 69 | $37,053 | $9,567 | 25.8% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 41 | 47 | $18,471 | $4,573 | 24.8% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 26 | 80 | $16,640 | $4,543 | 27.3% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2022 | 37 | 82 | $9,676 | $2,392 | 24.7% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 12 | 12 | $6,936 | $1,887 | 27.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 21 | 24 | $9,168 | $1,665 | 18.2% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2021 | 17 | 91 | $65,021 | $16,126 | 24.8% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 25 | 93 | $29,760 | $7,772 | 26.1% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 39 | 105 | $21,210 | $6,104 | 28.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 40 | 63 | $23,562 | $6,046 | 25.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 22 | 29 | $15,138 | $3,571 | 23.6% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 31 | 32 | $13,472 | $3,513 | 26.1% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 20 | 21 | $11,802 | $3,343 | 28.3% |
| 94060 | Measurement and graphic recording of the amount and speed of breathed air, before and following medication administration | Office | 2021 | 51 | 94 | $12,596 | $3,336 | 26.5% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 17 | 23 | $966.00 | $245.91 | 25.5% |
| J1040 | Injection, methylprednisolone acetate, 80 mg | Office | 2021 | 17 | 23 | $759.00 | $182.73 | 24.1% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2020 | 33 | 129 | $110,295 | $23,368 | 21.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 58 | 266 | $84,854 | $22,497 | 26.5% |
About Dr. Mark Co, MD
Dr. Mark Co, MD is a Pulmonary Disease healthcare provider based in Dallas, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/25/2005. The National Provider Identifier (NPI) number assigned to this provider is 1912990987.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Co, MD has received a total of $466.34 in payments from pharmaceutical and medical device companies, with $63.04 received in 2024. These payments were reported across 33 transactions from 9 companies. The most common payment nature is "Food and Beverage" ($441.05).
As a Medicare-enrolled provider, Co has provided services to 1,211 Medicare beneficiaries, totaling 2,892 services with total Medicare billing of $270,036. Data is available for 4 years (2020–2023), covering 35 distinct procedure/service records.
Ad
Practice Information
- Specialty Pulmonary Disease
- Location Dallas, TX
- Active Since 08/25/2005
- Last Updated 04/04/2011
- Taxonomy Code 207RP1001X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1912990987
Products in Payments
- LONHALA MAGNAIR (Drug) $108.78
- TRELEGY ELLIPTA (Drug) $100.58
- PURIFIED CORTROPHIN GEL (Drug) $81.58
- ACTHAR (Biological) $34.59
- ZERBAXA (Drug) $25.29
- NUCALA (Biological) $22.87
- OPSUMIT (Drug) $20.77
- OFEV (Drug) $17.37
- STIOLTO RESPIMAT (Drug) $14.54
- Valleylab (Device) $14.52
- SYMBICORT (Drug) $11.22
- ANORO ELLIPTA (Drug) $11.06
- Utibron (Drug) $3.17
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pulmonary Disease Doctors in Dallas
Dr. Mark Millard, M.d, M.D
Pulmonary Disease — Payments: $381,124
Pulmonary Disease $381,124
Dr. Fernando Torres, M.d, M.D
Pulmonary Disease — Payments: $247,706
Pulmonary Disease $247,706
Dr. Raksha Jain, Md, MD
Pulmonary Disease — Payments: $189,093
Pulmonary Disease $189,093
Dr. Kelly Chin, M.d, M.D
Pulmonary Disease — Payments: $103,886
Pulmonary Disease $103,886
Dr. Gary Weinstein, M.d, M.D
Pulmonary Disease — Payments: $102,068
Pulmonary Disease $102,068
Anthony Ortegon, Md, MD
Pulmonary Disease — Payments: $95,730
Pulmonary Disease $95,730